Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.

Carroll JP, Protani MM, Nguyen L, Cheng ME, Fay M, Saleem M, Pillay PS, Walpole E, Martin JH.

Med Oncol. 2014 Apr;31(4):881. doi: 10.1007/s12032-014-0881-z.

PMID:
24549982
2.

Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review.

Carroll J, Protani M, Walpole E, Martin JH.

Breast Cancer Res Treat. 2012 Nov;136(2):323-30. doi: 10.1007/s10549-012-2213-3. Review.

PMID:
22918525
4.
5.
6.

Undertreatment of obese women receiving breast cancer chemotherapy.

Griggs JJ, Sorbero ME, Lyman GH.

Arch Intern Med. 2005 Jun 13;165(11):1267-73.

PMID:
15956006
7.

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.

Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL.

J Clin Oncol. 1996 Nov;14(11):3000-8.

PMID:
8918498
8.

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.

Chaumard N, Limat S, Villanueva C, Nerich V, Fagnoni P, Bazan F, Chaigneau L, Dobi E, Cals L, Pivot X.

Breast. 2012 Aug;21(4):464-7. doi: 10.1016/j.breast.2011.10.009.

PMID:
22123411
9.

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB 3rd, Fuchs CS.

J Clin Oncol. 2004 Feb 15;22(4):648-57.

PMID:
14966087
10.

Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.

Cousin S, Le Rhun E, Mailliez A, Fournier C, Bonneterre J.

Bull Cancer. 2012 Jul-Aug;99(7-8):75-80. doi: 10.1684/bdc.2012.1607.

PMID:
22713627
11.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
12.

Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.

Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.

J Clin Oncol. 2003 Aug 15;21(16):3066-71.

PMID:
12915595
13.

Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Zauderer M, Howard J, Hudis C.

Breast Cancer Res Treat. 2005 Jul;92(2):151-6.

PMID:
15986124
14.

Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.

Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH.

JAMA Oncol. 2015 Sep;1(6):737-45. doi: 10.1001/jamaoncol.2015.1796.

15.

Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.

Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB.

Med Oncol. 2012 Sep;29(3):1495-501. doi: 10.1007/s12032-011-0035-5.

PMID:
21818673
16.

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

Ladoire S, Dalban C, Roché H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F.

Eur J Cancer. 2014 Feb;50(3):506-16. doi: 10.1016/j.ejca.2013.11.013.

PMID:
24315625
17.

[Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].

Abe H, Umeda T, Tanaka M, Kawai Y, Mori T, Cho H, Kubota Y, Mekata E, Kurumi Y, Tani T.

Gan To Kagaku Ryoho. 2010 Aug;37(8):1483-7. Japanese.

PMID:
20716872
18.

Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer.

Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU.

Ann Intern Med. 1994 Jan 1;120(1):18-25.

PMID:
8250452
19.

Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Hurria A, Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Howard J, Hudis C.

Drugs Aging. 2005;22(9):785-91.

PMID:
16156682
20.

Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity.

Jenkins P, Wallis R.

J Oncol Pharm Pract. 2010 Dec;16(4):251-5. doi: 10.1177/1078155209351304.

PMID:
19965948
Items per page

Supplemental Content

Support Center